Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H22O4.2Na |
Molecular Weight | 372.3658 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 7 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CC(\C=C\C=C(/C)C([O-])=O)=C/C=C/C=C(C)/C=C/C=C(\C)C([O-])=O
InChI
InChIKey=RMDMBHQVNHQDDD-VFWKRBOSSA-L
InChI=1S/C20H24O4.2Na/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24;;/h5-14H,1-4H3,(H,21,22)(H,23,24);;/q;2*+1/p-2/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+;;
Transcrocetinate (TSC) is a novel compound that offers promise as a treatment for conditions caused by hypoxia or ischemia. Unlike crocetin, it worked well in the more severe hemorrhagic shock model. Although many of the earlier studies with TSC involved the treatment of the ischemic conditions of hemorrhagic shock in both rats and swine, a few other studies involved treating purely hypoxic situations. One study showed that TSC was capable of promoting survival in rats breathing 10% oxygen. TSC also was able to increase arterial PO2 values in a rat model of acute respiratory distress syndrome (ARDS) caused by injection of oleic acid. The drug acts via a mechanism that has not been previously exploited in a pharmaceutical. TSC increases the rate of oxygen diffusion between the erythrocytes and the tissues by altering the 'structure' of water in blood plasma. It does this by causing additional hydrogen bonds to form among the water molecules. Animal toxicology studies have demonstrated that high levels of TSC are well-tolerated, and a Phase I clinical study has shown that TSC is also safe in humans. Delayed TSC treatment improves outcomes in experimental models of both ischemic and hemorrhagic stroke. TSC may be a safe and beneficial therapeutic modality for early stroke intervention, irrespective of the type of stroke involved. Transcrocetinate is in phase III clinical trial for the treatment of glioblastoma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16038536 |
28.0 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of trans sodium crocetinate on brain tumor oxygenation. Laboratory investigation. | 2009 Aug |
|
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide. | 2010 Aug |
|
Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator. | 2010 Jan 14 |
|
Trans sodium crocetinate alleviates ischemia/reperfusion-induced myocardial oxidative stress and apoptosis via the SIRT3/FOXO3a/SOD2 signaling pathway. | 2019 Jun |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
378312
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
345911
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
||
|
NCI_THESAURUS |
C68303
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL464792
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
YP57637WMX
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
C82695
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
DBSALT002610
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
591230-99-8
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
10287099
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
300000021773
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY | |||
|
AB-53
Created by
admin on Sat Dec 16 08:43:16 GMT 2023 , Edited by admin on Sat Dec 16 08:43:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD